Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind crossover trial of tivozanib hydrochloride versus sunitinib in metastatic renal cell carcinoma
2012-001730-33Phase 2Terminated
- Sponsor
- AVEO Oncology
- Start
- Sep 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tivozanib in metastatic renal cell carcinoma (mRCC) (2 arms), sponsored by AVEO Oncology. Primary endpoint: Subject treatment preference. Started Sep 2012; status: terminated.
02
Drugs
tivozanib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2012-001730-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001730-33.